title: Swallowing and speech ability after treatment for head and neck cancer with targeted intraarterial versus intravenous chemoradiation.
abstract: OBJECTIVE
  RADPLAT (concurrent selective supradose intraarterial cisplatin and external-beam irradiation) delivers extraordinarily high cisplatin concentration to head and neck structures. This study was designed to quantify and compare RADPLAT and systemic chemoradiation treatment effects on swallowing and speech.
  
  
  METHODS
  Videofluorographic swallowing studies and articulation testing of 14 head and neck cancer patients treated with RADPLAT were compared with 16 treated with systemic chemoradiation 1 month after treatment.
  
  
  RESULTS
  RADPLAT and systemic chemoradiation patients did not differ significantly on most swallow outcome measures, and there was significantly less aspiration on 1 and 3 mL liquid for RADPLAT individuals. Speech function was comparable except for RADPLAT's significantly worse /s, z/ productions.
  
  
  CONCLUSIONS
  Increased concentration of cisplatin to the head and neck did not result in generally reduced swallowing or articulatory function.
authors.affiliation: University of Tennessee College of Medicine, Memphis, Tennessee, USA.
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Newman
authors.forename: K Thomas
authors.initials: KT
authors.lastname: Robbins
authors.forename: Jeri A
authors.initials: JA
authors.lastname: Logemann
authors.forename: Alfred W
authors.initials: AW
authors.lastname: Rademaker
authors.forename: Cathy L
authors.initials: CL
authors.lastname: Lazarus
authors.forename: Annette
authors.initials: A
authors.lastname: Hamner
authors.forename: Stephanie
authors.initials: S
authors.lastname: Tusant
authors.forename: Cheng Fang
authors.initials: CF
authors.lastname: Huang
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003131:Combined Modality Therapy; D003680:Deglutition Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D015994:Incidence; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D008875:Middle Aged; D011336:Probability; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D012307:Risk Factors; D013064:Speech Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*
chemical_list: D002945:Cisplatin